Tipranavir

證據等級: L5

預測適應症: 10 個

Tipranavir: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome

One-Sentence Summary

Tipranavir (DB00932) is publicly known as a non-peptidic HIV-1 protease inhibitor, though the evidence pack itself contains a data gap for both the original indication and mechanism of action. The TxGNN model's top-ranked prediction is Feline Acquired Immunodeficiency Syndrome (FIV), a veterinary disease — this is not a viable human indication and reflects a species-specificity artifact in the knowledge graph rather than a genuine repurposing signal. No clinical trials or literature directly support this top prediction; the only substantively evidenced candidates (ranked #5–#6) are simply restatements of tipranavir's already-known HIV/AIDS indication, not new indications.

Quick Overview

Item	Content
Original Indication	Not available in dataset (data gap — no `approved_indication_text` on file; tipranavir is publicly known as an HIV-1 protease inhibitor for treatment-experienced patients)
Predicted New Indication	Feline Acquired Immunodeficiency Syndrome (veterinary; not human-applicable)
TxGNN Prediction Score	99.99%
Evidence Level	L5
Norway Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (flagged as a Blocking/High-severity data gap, DG001/DG002). Based on publicly known pharmacology referenced consistently throughout the evidence pack's own rationale text, tipranavir is a non-peptidic HIV-1 protease inhibitor that blocks cleavage of the viral Gag-Pol polyprotein, historically indicated for treatment-experienced HIV-1 infected adults.

The top-ranked prediction, feline acquired immunodeficiency syndrome (FIV), scores extremely high in TxGNN but is a veterinary, species-specific disease. The similarity driving this score is a structural homology between HIV-1 and lentiviral (FIV) proteases — a known graph-embedding artifact where the model conflates cross-species protease homology with therapeutic relevance. This pathway has no human clinical development route and should not be interpreted as a genuine repurposing opportunity. The same pattern explains ranks #2–#4 and #7–#10 (SIV infection, a rare neurodevelopmental disorder, an obsolete hyperlipidemia diagnosis, and several unrelated benign tumors): none have a plausible mechanistic link to protease inhibition, and several (e.g., hyperlipidemia) are mechanistically contradicted by tipranavir's known lipid-related adverse effect profile.

The only candidates with any substantive evidence base are ranked #5 ("AIDS related complex") and #6 ("congenital human immunodeficiency virus"), both scored L4/S1 ("Research Question"). However, these are not new indications — they are historical/pediatric classifications within HIV/AIDS, the disease area tipranavir is already known to treat. Rank #6's supporting trials are almost entirely for other antiretrovirals (cabotegravir, dolutegravir, rilpivirine) and provide only class-level, not drug-specific, support.

Clinical Trial Evidence

Currently no related clinical trials registered.

(Note: the top-ranked prediction, FIV, has no clinical trial evidence, as expected for a non-human disease. The more mechanistically coherent but non-novel candidate "congenital human immunodeficiency virus" has 9 associated trials, none specific to tipranavir — see rationale above.)

Literature Evidence

Currently no related literature available.

Norway Market Information

Tipranavir is not currently marketed in Norway (market_status: 未上市) and has 0 registered authorizations. No license records are available for this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction (FIV) is a veterinary disease with no plausible human development pathway, and none of the remaining top-10 predictions constitute a credible, evidence-backed new human indication — the only scientifically coherent candidates (AIDS related complex, congenital HIV) simply restate tipranavir's known HIV/AIDS indication rather than reveal novel therapeutic potential. Combined with the Blocking-severity absence of TFDA/official label data, this candidate does not meet the bar to advance past S1 screening.

To proceed, the following is needed:

Official label/monograph data (TFDA or equivalent) to resolve DG001 (warnings/contraindications) and DG002 (MOA)
Confirmed original indication data to enable a valid MOA-to-new-indication comparison
Re-run of TxGNN filtering to exclude non-human disease nodes and restatements of the drug's known indication before ranking is considered actionable
If a genuinely novel indication is desired, evaluate lower-ranked candidates with independent mechanistic plausibility beyond protease-homology artifacts
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.